LKT Labs

Biochemicals for Life Science Research

(Z)-4-Hydroxytamoxifen

(Z)-4-Hydroxytamoxifen

Product ID H9711
Cas No. 68047-06-3
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $165.30 In stock
10 mg $275.30 In stock
25 mg $572.40 In stock
Bulk Quote

Quicklinks

Description

(Z)-4-Hydroxytamoxifen is the more active isomer of 4-hydroxytamoxifen. 4-Hydroxytamoxifen is the active metabolite of tamoxifen, a selective estrogen receptor modulator (SERM) that acts as an agonist or antagonist in various tissues. 4-Hydroxytamoxifen exhibits anticancer chemotherapeutic activity, inducing autophagy and vacuole formation as well as KRAS degradation in various cancer cell lines. In cardiac myocytes, 4-hydroxytamoxifen decreases Ca2+ amplitude, slowing relaxation and decreasing contractility.

Product Info

Cas No.

68047-06-3
Purity

≥98%
Formula

C26H29NO2
Formula Wt.

387.51
IUPAC Name

4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
Melting Point

142-144°C
Solubility

Soluble in DMSO, ethanol (20mg/ml) or methanol (10mg/ml); insoluble water.
Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

H9711 MSDS PDF
Info Sheet

H9711 Info Sheet PDF

References

Asp ML, Martindale JJ, Metzger JM. Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling. PLoS One. 2013 Oct 24;8(10):e78768. PMID: 24205315.

Kohli L, Kaza N, Coric T, et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res. 2013 Jul 15;73(14):4395-405. PMID: 23722551.

Schwartz JA, Zhong L, Deighton-Collins S, et al. Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen. J Biol Chem. 2002 Apr 12;277(15):13202-9. Erratum in: J Biol Chem 2002 Jul 5;277(27):24842. PMID: 11823467.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A4441

    Allicin, aqueous solution

    Organosulfur found in garlic; Kir K+ channel ac...

    ≥98%
  • V0245

    Valdecoxib

    NSAID; CB1 agonist, COX-2 inhibitor.

    ≥98%
  • L337521

    Linagliptin

    Modifies microvascular function

    ≥98%
  • C1644

    Celecoxib

    NSAID; COX-2 inhibitor.

    ≥99%
  • F1654

    Fenoldopam Mesylate

    Benzazepine derivative; D1 partial agonist, pot...

    ≥98%
  • C0048

    Cambinol

    SIRT inhibitor.

    ≥98%
  • C3246

    Cilostazol

    Quinoline; PDE 3B inhibitor.

    ≥98%
  • B1996

    BEZ235

    PI3K and mTOR inhibitor.

    ≥98%
  • N3378

    S-Nitrosoglutathione

    NO donor.

    ≥95%
  • P2859

    Phosphate Acceptor Peptide

    PKC and S6 kinase substrate.

    ≥95%
  • B8070

    2-tert-Butyl-4-Hydroxyanisole

    BHA derivative, antioxidative food and cosmetic...

    ≥99% single isomer
  • I0502

    Ibandronate Sodium Monohydrate

    Bisphosphonate.

    ≥98%
  • F1607

    Febuxostat

    Xanthine oxidase inhibitor.

    ≥98%
  • I525138

    Indoximod

    Indoleamine 2,3-dioxygenase inhibitor.

    ≥98%
  • F4482

    Fluvastatin Sodium

    Statin; HMG-CoA reductase inhibitor, potential ...

    ≥98%
  • D5746

    Dolasetron

    5-HT3 antagonist.

    ≥98%
  • M1873

    S-(N-Methylsulfinylbutylthiocarbamoyl)-L-cysteine

    Sulforaphane-cysteine conjugate.

    ≥98%
  • D019601

    Dapagliflozin

    SGLT2 inhibitor

    ≥98%
  • L5993

    Loxoprofen Sodium Dihydrate

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • G124080

    GDC-0994

    ERK1/2 inhibitor.

    ≥98%